INS and type 2 diabetes mellitus: In subsequent cell-based experiments, TSME-1 continued to show strong capacity for GLP-1 receptor activation including cAMP stimulation, insulin release enhancement and pancreatic islet cell proliferation, thus indicating that it may have a positive effect in treating T2D when administered orally [38].